Regulatory Pressure Mounts for Telehealth Firm Hims & Hers

The telehealth company Hims & Hers finds itself navigating a significant regulatory challenge following action by the U.S. Food and Drug Administration (FDA). This development casts a shadow over the firm’s otherwise impressive growth trajectory, raising questions about the impact on its future performance.

Despite the emerging regulatory concerns, the company’s operational results for the second quarter of 2025 were exceptionally strong. The financial and subscriber metrics underscore its rapid expansion:

• Revenue reached $544.8 million, representing a substantial 73% year-over-year increase.
• The subscriber base grew to over 2.4 million, a 31% jump compared to the previous year.
• Net income was reported at $42.5 million.
• Management has reaffirmed its full-year... Read more...